Immuneering Corporation

Contributing Author

Recent Articles by Immuneering Corporation

5 hours	Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO IMRX -23.07% GlobeNewswire
May-21	Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy IMRX GlobeNewswire
May-15	Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates IMRX GlobeNewswire
Apr-21	Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting IMRX +6.13% IMRX GlobeNewswire
Apr-20	Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond IMRX GlobeNewswire
Apr-06	Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference IMRX GlobeNewswire
Mar-17	Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival IMRX GlobeNewswire
Mar-06	Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates IMRX +7.03% GlobeNewswire
Mar-02	Immuneering to Present at the Leerink Global Healthcare Conference IMRX GlobeNewswire
Feb-18	Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference IMRX GlobeNewswire
Jan-07	Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP IMRX -43.22% IMRX +23.96% GlobeNewswire
Dec-23	Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 IMRX +8.12% GlobeNewswire
Dec-17	Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA IMRX GlobeNewswire
Dec-16	Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) IMRX GlobeNewswire
Nov-25	Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference IMRX GlobeNewswire
Nov-12	Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates IMRX GlobeNewswire
Nov-04	Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 IMRX GlobeNewswire
Sep-26	Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 IMRX -16.46% IMRX GlobeNewswire
Sep-25	Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi IMRX -13.33% GlobeNewswire
Sep-24	Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi IMRX +7.45% GlobeNewswire
Sep-24	Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP IMRX -13.33% IMRX +7.45% GlobeNewswire
Sep-16	Immuneering Appoints Dr. Thomas Schall as Chairman of the Board IMRX +5.73% GlobeNewswire
Sep-10	Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25 IMRX +15.46% GlobeNewswire
Aug-26	Immuneering Announces Closing of $25 Million Private Placement IMRX -12.33% IMRX GlobeNewswire
Aug-25	Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib IMRX +21.68% GlobeNewswire
Aug-21	Immuneering Announces $25 Million Private Placement IMRX +34.99% GlobeNewswire
Aug-13	Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates IMRX -5.59% IMRX GlobeNewswire
Jul-09	Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib IMRX +11.25% GlobeNewswire
Jun-17	Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients IMRX -23.21% GlobeNewswire
Jun-16	Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 IMRX +24.74% GlobeNewswire
May-29	Immuneering to Present at the Jefferies Global Healthcare Conference IMRX -5.83% GlobeNewswire
May-05	Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates IMRX GlobeNewswire

Immuneering Corporation

Recent Articles by Immuneering Corporation

Upgrade your Finviz experience